PURPOSE: ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients. EXPERIMENTAL DESIGN: Using denaturing high-performance liquid chromatography and sequencing, we screened for ABL kinase domain mutations in 370 Ph+ patients with evidence of hematologic or cytogenetic resistance to imatinib. RESULTS: Mutations were found in 127 of 297 (43%) evaluable patients. Mutations were found in 27% of chronic-phase patients (14% treated with imatinib frontline; 31% treated with imatinib post-IFN failure), 52% of accelerated-phase patients, 75% of myeloid blast crisis patients, and 83% of lymphoid blast crisis/Ph+ acute lymphoblastic leukemia (ALL) patients. Mutations were associated in 30% of patients with primary resistance (44% hematologic and 28% cytogenetic) and in 57% of patients with acquired resistance (23% patients who lost cytogenetic response; 55% patients who lost hematologic response; and 87% patients who progressed to accelerated phase/blast crisis). P-loop and T315I mutations were particularly frequent in advanced-phase chronic myeloid leukemia and Ph+ ALL patients, and often accompanied progression from chronic phase to accelerated phase/blast crisis. CONCLUSIONS: We conclude that (a) amino acid substitutions at seven residues (M244V, G250E, Y253F/H, E255K/V, T315I, M351T, and F359V) account for 85% of all resistance-associated mutations; (b) the search for mutations is important both in case of imatinib failure and in case of loss of response at the hematologic or cytogenetic level; (c) advanced-phase chronic myeloid leukemia and Ph+ ALL patients have a higher likelihood of developing imatinib-resistant mutations; and (d) the presence of either P-loop or T315I mutations in imatinib-treated patients should warn the clinician to reconsider the therapeutic strategy.
PURPOSE:ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemiapatients. EXPERIMENTAL DESIGN: Using denaturing high-performance liquid chromatography and sequencing, we screened for ABL kinase domain mutations in 370 Ph+ patients with evidence of hematologic or cytogenetic resistance to imatinib. RESULTS: Mutations were found in 127 of 297 (43%) evaluable patients. Mutations were found in 27% of chronic-phase patients (14% treated with imatinib frontline; 31% treated with imatinib post-IFN failure), 52% of accelerated-phase patients, 75% of myeloid blast crisis patients, and 83% of lymphoid blast crisis/Ph+ acute lymphoblastic leukemia (ALL) patients. Mutations were associated in 30% of patients with primary resistance (44% hematologic and 28% cytogenetic) and in 57% of patients with acquired resistance (23% patients who lost cytogenetic response; 55% patients who lost hematologic response; and 87% patients who progressed to accelerated phase/blast crisis). P-loop and T315I mutations were particularly frequent in advanced-phase chronic myeloid leukemia and Ph+ ALL patients, and often accompanied progression from chronic phase to accelerated phase/blast crisis. CONCLUSIONS: We conclude that (a) amino acid substitutions at seven residues (M244V, G250E, Y253F/H, E255K/V, T315I, M351T, and F359V) account for 85% of all resistance-associated mutations; (b) the search for mutations is important both in case of imatinib failure and in case of loss of response at the hematologic or cytogenetic level; (c) advanced-phase chronic myeloid leukemia and Ph+ ALL patients have a higher likelihood of developing imatinib-resistant mutations; and (d) the presence of either P-loop or T315I mutations in imatinib-treated patients should warn the clinician to reconsider the therapeutic strategy.
Authors: A A Mian; A Rafiei; I Haberbosch; A Zeifman; I Titov; V Stroylov; A Metodieva; O Stroganov; F Novikov; B Brill; G Chilov; D Hoelzer; O G Ottmann; M Ruthardt Journal: Leukemia Date: 2014-11-14 Impact factor: 11.528
Authors: E A Lasater; E S Massi; A Stecula; J Politi; S K Tan; C C Smith; M Gunthorpe; J P Holmes; F Chehab; A Sali; N P Shah Journal: Leukemia Date: 2015-10-29 Impact factor: 11.528
Authors: Emily F Mason; Yuxing Zhao; Pankuri Goraksha-Hicks; Jonathan L Coloff; Hugh Gannon; Stephen N Jones; Jeffrey C Rathmell Journal: Cancer Res Date: 2010-09-28 Impact factor: 12.701
Authors: Jamshid S Khorashad; Todd W Kelley; Philippe Szankasi; Clinton C Mason; Simona Soverini; Lauren T Adrian; Christopher A Eide; Matthew S Zabriskie; Thoralf Lange; Johanna C Estrada; Anthony D Pomicter; Anna M Eiring; Ira L Kraft; David J Anderson; Zhimin Gu; Mary Alikian; Alistair G Reid; Letizia Foroni; David Marin; Brian J Druker; Thomas O'Hare; Michael W Deininger Journal: Blood Date: 2012-12-05 Impact factor: 22.113
Authors: Martin C Müller; Jorge E Cortes; Dong-Wook Kim; Brian J Druker; Philipp Erben; Ricardo Pasquini; Susan Branford; Timothy P Hughes; Jerald P Radich; Lynn Ploughman; Jaydip Mukhopadhyay; Andreas Hochhaus Journal: Blood Date: 2009-09-24 Impact factor: 22.113